1. Wang, Shih-Ho, Yeh, Cheng-Hsi, Wu, Chia-Wei, Wang, Yi-Wen, Hsieh, Tsung-Hua. 2024. PFDN4 as a Prognostic Marker Was Associated with Chemotherapy Resistance through CREBP1/AURKA Pathway in Triple-Negative Breast Cancer. In International journal of molecular sciences, 25, . doi:10.3390/ijms25073906. https://pubmed.ncbi.nlm.nih.gov/38612711/
2. Ye, Jing, Wang, Jianguo, Liu, Rongqiang, Chen, Chen, Wang, Weixing. 2024. The prognostic significance and potential mechanism of PFDN4 in hepatocellular carcinoma. In International immunopharmacology, 145, 113761. doi:10.1016/j.intimp.2024.113761. https://pubmed.ncbi.nlm.nih.gov/39644788/
3. Miyoshi, Norikatsu, Ishii, Hideshi, Mimori, Koshi, Doki, Yuichiro, Mori, Masaki. 2010. Abnormal expression of PFDN4 in colorectal cancer: a novel marker for prognosis. In Annals of surgical oncology, 17, 3030-6. doi:10.1245/s10434-010-1138-5. https://pubmed.ncbi.nlm.nih.gov/20552408/
4. Yesseyeva, Galiya, Aikemu, Batuer, Hong, Hiju, Zheng, Minhua, Ma, Junjun. . Prefoldin subunits (PFDN1-6) serve as poor prognostic markers in gastric cancer. In Bioscience reports, 40, . doi:10.1042/BSR20192712. https://pubmed.ncbi.nlm.nih.gov/31957800/
智鼠故事 
